Medtronic and Covidien are nearing the finish line of their pending $43 billion merger as Medtronic shareholders voted on Tuesday to approve the deal, following in the footsteps of a similar vote from Covidien shareholders.

“We’re extremely pleased with the positive vote we received today by our shareholders,” Medtronic CEO Omar Ishrak said in a statement. “We are convinced that the addition of Covidien’s people and technologies will allow us to expedite our strategic initiative and will allow us to treat more people, in more ways and in more places around the world. We look forward to closing this transaction by the end of January or early February.”